drugset / Trial / NCT07346157
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
Timeline
- Start
- 2026-07-30
- Primary completion
- 2031-03-31
- Completion
- 2031-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liothyronine | Small molecule | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Temozolomide | Small molecule | — | — |